Stockscreener 앱 받기
91.67
0.86%
-1.01
전일 마감가:
$92.68
열려 있는:
$92.82
하루 거래량:
199.44K
Relative Volume:
0.16
시가총액:
$8.10B
수익:
$688.00K
순이익/손실:
$-168.74M
주가수익비율:
-38.88
EPS:
-2.3577
순현금흐름:
$-185.87M
1주 성능:
+1.41%
1개월 성능:
-14.79%
6개월 성능:
+113.37%
1년 성능:
+499.73%
1일 변동 폭
$91.28
$93.34
1주일 범위
$88.47
$95.19
52주 변동 폭
$14.51
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
91.89 | 7.99B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
507.21 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
786.64 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
996.27 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
155.13 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
191.21 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Raymond James | Strong Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Yahoo Finance
Spyre Therapeutics at Wells Fargo conference: betting on combination biologics - Investing.com Canada
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Spyre Therapeutics at Citi summit: bets on autoimmune combinations By Investing.com - Investing.com Canada
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - The Globe and Mail
Spyre Therapeutics Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com South Africa
SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada
Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com
An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan
Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Yahoo Finance
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Announces Grants of Inducement Awards - manilatimes.net
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares - investing.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares - investing.com
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares - Investing.com
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares By Investing.com - Investing.com India
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells over 25K shares in planned trades - Stock Titan
Spyre Therapeutics (SYRE) officer sells stock from option exercise at prices up to $90 - Stock Titan
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Three September conferences will include Spyre Therapeutics. Webcasts will be available. - Stock Titan
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Multimillion-dollar stock sale planned by Spyre Therapeutics (SYRE) officer—see how many shares are on the block - Stock Titan
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked - finance.yahoo.com
Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles - Sahm
Spyre reveals mid-stage miss for TL1A antibody in rheumatoid arthritis - The Pharma Letter
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis - TradingView
Stifel reiterates Spyre stock Buy rating after RA study results By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127 - Moomoo
Stifel reiterates Spyre stock Buy rating after RA study results - Investing.com
Deutsche Bank Adjusts Spyre Therapeutics PT to $127 From $135, Maintains Buy Rating - marketscreener.com
Why is Spyre Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Spyre reports mixed phase 2 results for SPY072 in arthritis By Investing.com - Investing.com Nigeria
Stocks to Watch : Intuit, Spyre Therapeutics, Zoom Communications, nCino - marketscreener.com
Spyre Therapeutics stock tumbles on trial results By Investing.com - Investing.com Australia
Spyre reports mixed phase 2 results for SPY072 in arthritis - Investing.com
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 - The Manila Times
Spyre Therapeutics reports statistically significant Phase 2 RA signals for SPY072 but will not prioritize monotherapy - TradingView
Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, NCino - Moomoo
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk? - Yahoo Finance
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.22%
자본화:
|
볼륨(24시간):